Alan L. Kaganov, Sc.D, joined US Venture Partners in July 1996, as a Partner, after 25 years of operating experience in the healthcare industry. At USVP, Dr. Kaganov focuses on early stage investments in medical devices, drug-device combinations and drug delivery systems. Alan transitioned to Senior Advisor in 2015.
Dr. Kaganov’s board activities have included: Atricure (NASDAQ: ATRC); CryoVascular Systems (sold to Boston Scientific); St. Francis Medical (sold to Kyphon/Medtronic); AtheroMed (sold to Volcano/Phillips); and Aptus Endosystems (sold to Medtronic). In each case, Alan/USVP was the first institutional investor.
Prior to joining USVP, Dr. Kaganov led Business Development and Strategic Planning at Boston Scientific Corporation. Prior to BSC, he was CEO of EP Technologies, and transformed the Company into the recognized leader in catheter-based arrhythmia treatment. Prior to this, Dr. Kaganov spent six years at Baxter International initially as General Manager, Fenwal Division and then Vice President of Technology and Business Development of Baxter International.
Dr. Kaganov serves on the Medical Advisory Board of Flex, the multi-national contract manufacturer, and as Board Advisor to Spinal Elements, Inc., Carlsbad, CA.
He holds a B.S. in Mechanical Engineering from Duke University, an M.S. and Sc.D. in Biomedical Engineering from Columbia University, and an M.B.A. from New York University. Alan received a Career Fellowship from the National Institutes of Health in Biomedical Engineering. Alan serves as a Board Member of the Gladstone Institutes, where research is focused on unsolved diseases with profound medical, economic, and social impact.
Dr. Kaganov holds 15 U.S. patents. He served on the Board of Visitors of Pratt School of Engineering, Duke University for 12 years. Alan received the Distinguished Alumnus Award in 2005. He now serves on the Engineering Advisory Board, of Columbia University.